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Edited by Veli-Pekka LehtoAbstract A link between macrophage migration inhibitory fac-
tor (MIF) and estrogen has recently emerged. We examined the
involvement of MIF in osteoporotic changes in bone after ovar-
iectomy (OVX), and revealed that MIF-deﬁcient mice (MIF-
KO) were completely protected from this phenomenon. The
increase in osteoclast number per bone surface and serum IL-
1b levels, which were observed in wild-type mice after OVX,
did not occur in MIF KO. Our data suggest that MIF plays
an important role in the pathogenesis of postmenopausal osteo-
porosis, and could be a novel target for the treatment of this
disease.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Postmenopausal osteoporosis is one of the major health
problems aﬀecting elderly women in developed countries.
Estrogen deﬁciency results in an increase in bone turnover,
leading to bone resorption and an increased risk of fracture [1].
There is now a large body of evidence suggesting that estro-
gen deﬁciency after natural or surgical menopause increases
proinﬂammatory cytokines such as interleukin (IL)-1, IL-6,
and tumor necrosis factor (TNF)-a [2–5]. These proinﬂamma-
tory cytokines enhance osteoclast formation and activate ma-
ture osteoclasts, resulting in increased bone resorption [6,7].
In addition, animal models have shown that the deﬁciency or
the functional block of one of these cytokines prevents the
bone loss induced by ovariectomy (OVX) [8].Abbreviations: MIF, macrophage migration inhibitory factor; OVX,
ovariectomy; WT, wild-type; IL, interleukin; TNF, tumor necrosis
factor; KO, knock out; ELISA, enzyme-linked immunosorbent assay
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doi:10.1016/j.febslet.2006.01.038Macrophage migration inhibitory factor (MIF) was initially
identiﬁed as a soluble factor in culture medium of activated T
cells [9,10]. Following the cloning of MIF cDNA [11], the
novel biological functions of MIF have been reported. MIF
is released as a proinﬂammatory cytokine and a glucocorti-
coid-induced immunomodulator in response to a variety of
inﬂammatory stimuli [12–14]. Recently, a link between MIF
and estrogen has emerged. It was reported that MIF was
upregulated in the wound healing process of estrogen-deﬁcient
mice, and that estrogen decreased MIF production by murine
macrophages [15].
OVX-induced osteoporosis is a model for postmenopausal
osteoporosis. The purpose of this study is to examine the role
of MIF in this process by comparing the eﬀect of OVX be-
tween wild-type mice (WT) and MIF knock-out mice (MIF-
KO).2. Materials and methods
2.1. Animals
In the present study, we used MIF-deﬁcient mutant mice with gen-
eration numbers of F11 to F13 from a mouse strain (bred onto a
Balb/c background) deﬁcient in the MIF gene, which was established
by Honma et al. [16]. In brief, they generated a gene targeting vector
containing the endogenous MIF gene in which a 201-bp SacI fragment
consisting of the 3 0 region of exon 1 and the 5 0 region of intron 1 was
replaced with a pMCI-neo poly (A) cassette in a forward orientation
relative to MIF gene transcription. R1 embryonic stem (ES) cells were
transected and subjected to positive selection. Subsequently, they gen-
erated germ line chimeras with targeted disruption of the MIF gene by
the aggregation method, and they established a mouse strain deﬁcient
in MIF gene. To achieve a pure strain of the Balb/c background on
MIF KO mice, backcrossing was performed more than 10 times. These
mice developed normally and appeared healthy. Macroscopic and
microscopic examinations of ovary and uterus from homozygous mu-
tants revealed no signiﬁcant abnormalities (data not shown). Balb/c
WT mice were purchased from Sankyo Lab. (Japan) and maintained
under speciﬁc pathogen-free conditions. Eight-week-old female WT
and MIF KO mice were used in all experiment. All mice were main-
tained under speciﬁc pathogen-free conditions. All animal procedures
were conducted according to the guidelines of the Hokkaido Univer-
sity Institutional Animal Care and Use Committee, using an approved
protocol. Bilateral OVX or sham surgeries (n = 5–8) were performed
under anesthesia. Four weeks after surgery, all the mice were sacriﬁced
by means of an overdose of anesthesia.blished by Elsevier B.V. All rights reserved.
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Right femora were ﬁxed in 10% formaldehyde after the removal of
soft tissues and were analyzed by a Microcomputed tomography
(lCT) system (Hitachi Medical Corporation, Tokyo, Japan). The
two-dimensional image of the trabecular bone was quantiﬁed as fol-
lows. Axial bone slices were made with a thickness of 16 lm in the area
of 0.7 mm · 1.0 mm · 1.3 mm proximal from the distal growth plate of
the femora. The mean volume (bone volume/tissue volume; BV/TV),
number, and separation of the trabecular bone at the areas of the three
slices mentioned above were quantiﬁed by an image analyzer (KGT,
Tokyo, Japan).
2.3. Histomorphometric analysis of bone
For histological analysis, serial 5 lm sections of proximal tibiae were
made and stained for hematoxylin/eosin (H-E). For bone histomor-
phometric analysis, mice were injected subcutaneously with 8 mg/kg
body weight of calcein at 4 and 1 day before killing. The right tibia re-
moved from each mouse was ﬁxed with 70% ethanol and embedded in
methyl methacrylate without decalciﬁcation. The ﬁxed tibia was sec-
tioned (5 lm) serially using the microtome, and the sections were then
stained by Villanueva–Goldner’s trichrome method for discrimination
between mineralized and unmineralized bones and also for identiﬁca-
tion of cellular components. Stained bone sections were analyzed using
an image analyzer (System Supply Co.). The measurements were done
in an area 1.2 mm in length from 0.3 mm below the growth plate at the
proximal metaphysis of the tibiae, and histomorphometry was con-
ducted as previously deﬁned [17]. The parameters measured for bone
structures were the total bone volume per tissue volume (BV/TV, %),
trabecular number (Tb.N, lm), and trabecular separation (Tb.Sp,
lm). The parameters obtained for the bone formation were the osteoid
surface per bone surface (OS/BS, %), the osteoblast surface per bone
surface (Ob.S/BS, %), mineral apposition rate (MAR, per day), and
bone formation rate per bone surface (BFR/BS, mm3/cm2/y). The
parameters measured for bone resorption were the eroded surfaceMIF KO
wild type
sham
A
C
Fig. 1. lCT analysis of the right femora of mice at 4 weeks after OVX or sha
(C) MIF KO, sham-operated. (D) MIF KO, OVX. Axial bone slices of femur
to the distal growth plate of the femora are shown.per bone surface (ES/BS, %), the osteoclast surface per bone surface
(Oc.S/BS, %), and number of osteoclasts per the bone perimeter
(N.Oc/B.Pm, per 100 mm).
2.4. Serum cytokine levels
The serum contents of IL-1b, IL-6, and TNF-a were measured using
enzyme-linked immunosorbent assay (ELISA) kits (BioSource Interna-
tional, CA, USA), and the serum contents of MIF using an ELISA kit
(Sapporo Immuno Diagnostic Laboratory, Sapporo, Japan), accord-
ing to the manufacturer’s instructions.
The data were evaluated for statistical signiﬁcance by one-way AN-
OVA using Fisher’s test as a post hoc test. A P-value of <0.05 was con-
sidered to be statistically signiﬁcant.3. Results
3.1. Trabecular bone loss in distal femur
lCT examination of femoral bones revealed the eﬀect of
OVX in WT mice. As expected, compared with the sham-oper-
ated controls, the distal femoral trabecular bones of OVX mice
were signiﬁcantly reduced (Fig. 1A and B) in each correspond-
ing axial slice. On the other hand, in MIF KO, the decrease in
trabecular bones induced by OVX was completely avoided
(Fig. 1C and D). Quantiﬁcation of trabecular bones showed
that BV/TV of the WT and MIF KO after sham operation
were not diﬀerent, and that of WT after OVX was signiﬁcantly
reduced compared with the sham-operated WT (47% reduc-
tion, P < 0.05, Fig. 2A). No signiﬁcant BV/TV reduction was
seen in MIF KO after OVX (Fig. 2A). Trabecular bone num-OVX
B
D
m operation. (A) WT, sham-operated. (B) WT, ovariectomised (OVX).
were made as described in Section 2. The slices made 1.0 mm proximal
Fig. 2. Quantiﬁcation of two-dimensional lCT-based values. (A) The OVX-induced reductions in BV/TV were prevented in MIF KO. (B) MIF KO
were also protected from the decrease in the trabecular number following OVX. (C) The OVX-induced increase in trabecular separation was also
prevented in MIF KO. Values are means ± S.D. n = 8 in all groups; *P < 0.05 vs. WT-sh, MIF KO-sh, MIF KO-sh.
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P < 0.01, Fig. 2B), and trabecular separation was also in-
creased about 1.6-fold over that of the sham-operated mice
(P < 0.05, Fig. 2C). In MIF KO, these changes were not ob-
served between OVX and sham-operated ones.
3.2. Bone histomorphometry in WT and MIF KO
It was apparent from the histological observations that the
cancellous bone volume in the proximal region of the tibiae
was reduced in WT after OVX (Fig. 3A and B), whereas this
reduction did not occur in MIF KO-OVX compared with
MIF KO-sham (Fig. 3C and D). These losses of reduction of
trabecular bone in MIF KO-OVX were further conﬁrmed by
bone histomorphometry (Table 1). The parameters for bone
resorption, i.e., Oc.S/BS and N.Oc/B.Pm, were signiﬁcantly in-
creased by OVX (P < 0.01 and 0.05, respectively), whereas
these increase did not occur in the absence of MIF. Accord-
ingly, the parameters for bone resorption after OVX were sig-
niﬁcantly lower in MIF KO than in WT (P < 0.05). On the
other hand, the parameters for bone formation and bone turn-
over were similar or slightly increased to some extent, though
not signiﬁcant, in WT and MIF KO after OVX. These sug-
gested that in MIF KO, the capacity for osteoblastogenesis
or bone formation was not harmed.
3.3. Changes of serum proinﬂammatory cytokines after OVX
The levels of serum IL-1b, IL-6, and TNF-a were also mea-
sured at 4 weeks after OVX by ELISA. In WT after OVX,serum IL-1b levels were signiﬁcantly increased, compared with
the levels in sham-operated mice (96% increase, P < 0.05;
Fig. 4), while in MIF KO there was no signiﬁcant diﬀerence
between the OVX and control groups. The changes of serum
TNF-a or IL-6 were not observed in this series of experiments
(data not shown).
3.4. Eﬀect of estrogen depletion on MIF production
Next, we investigated whether OVX induced an increase in
the serum MIF level in WT. The serum MIF was signiﬁcantly
increased at 24 h after OVX compared with sham-operated
mice, while at 7 days after OVX, this increase was not observed
(Fig. 5).4. Discussion
In this study, we demonstrated for the ﬁrst time that MIF
is required for the bone loss induced by estrogen depletion
after OVX, a model for postmenopausal osteoporosis, using
MIF KO. As shown in our data, OVX did not aﬀect indices
related to bone structure or bone turnover. It is widely ac-
cepted that after menopause, the depletion of estrogen
causes a high bone-turnover state that leads the bone meta-
bolic balance to resorption, which results in osteoporosis
[18,19]. Histomorphometry of the tibiae revealed that in
WT, OVX-induced bone loss was associated with the in-
crease in osteoclastic bone resorption. In contrast, in MIF
MIF KO
wild type
sham OVX
A B
C D
Fig. 3. Sections of trabecular bone of proximal tibiae stained for H-E. (A) WT, sham-operated. (B) WT, OVX. (C) MIF KO, sham-operated.
(D) MIF KO, OVX.
Table 1
Changes in proximal tibial bone histomorphometric parameters in WT and MIF KO mice
Bone parameters WT-sham WT-OVX MIF KO-sham MIF KO-OVX
Static parameters
BV/TV (%) 6.95 ± 2.06 3.66 ± 1.75a 4.91 ± 1.86 5.65 ± 0.61
Tb.N (lm) 2.38 ± 0.93 1.32 ± 0.19a 1.84 ± 0.46 2.03 ± 0.16
Tb.Sp (lm) 456 ± 171 906 ± 429a 546 ± 120 469 ± 38.2
Formation parameters
OS/BS (%) 3.46 ± 0.49 7.42 ± 4.25 4.70 ± 3.30 5.11 ± 1.99
Ob.S/BS (%) 7.29 ± 1.55 8.79 ± 3.91 7.76 ± 2.84 11.12 ± 3.14
MAR (per day) 1.77 ± 0.19 1.95 ± 0.16 1.42 ± 0.20d 1.54 ± 0.23c
BFR/BS (mm3/cm2/y) 13.76 ± 3.86 13.38 ± 5.64 7.72 ± 3.23 11.85 ± 2.13
Resorption parameters
ES/BS (lm) 7.57 ± 3.33 11.00 ± 2.46 4.45 ± 2.99c 4.77 ± 2.50c
Oc.S/BS (%) 1.61 ± 0.80 5.10 ± 1.62b 2.72 ± 1.91 2.22 ± 0.61c
N.Oc/B.Pm (per 100 mm) 138 ± 44.4 352 ± 147a 223 ± 107 122 ± 17.5c
Values are shown as means ± S.D. (n = 5 per group).
aSigniﬁcantly diﬀerent from WT-sham (P < 0.05).
bSigniﬁcantly diﬀerent from WT-sham (P < 0.01).
cSigniﬁcantly diﬀerent from WT-ovx (P < 0.05).
dSigniﬁcantly diﬀerent from WT-ovx (P < 0.01).
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the absence of the increase in osteoclastic bone resorption,
as shown by the absence of an increase in N.Oc/B.Pm and
Oc.S/BS after OVX.We observed rapid enhancement of serum MIF levels fol-
lowing OVX. Several lines of evidence show very rapid in-
crease of MIF production after various stimuli. Matsuda
et al. reported the immunohistochemical localization of MIF
Fig. 4. Eﬀect of OVX on serum IL-1b levels at 4 weeks after OVX or
sham operation. Values are means ± S.D. n = 5 in all groups; *P < 0.05
vs. WT-sh and MIF KO-sh, *P < 0.01 vs. MIF KO-OVX.
Fig. 5. MIF concentrations in serum collected at 24 h and 7 days after
OVX. MIF levels were signiﬁcantly increased in WT-OVX at 24 h
compared with WT-sh. Values are means ± S.D. n = 5 in all groups at
24 h and at 7 days. *P < 0.05 vs. WT-sh at 24 h.
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after injury in a rat corneal wound-healing model [20,21]. Sim-
ilar observations showing rapid upregulation of MIF expres-
sion after various stimuli have also been reported in in vivo
and in vitro experiments [12,22]. Our results showed that
OVX is another stimulus that rapidly induces the secretion
of MIF. Estrogen deﬁciency increases bone-resorbing mole-
cules such as IL-1, IL-6, and TNF-a, which causes increased
bone resorption after OVX [4–7]. On the other hand, there
have been no reports so far concerning the direct action of
MIF on bone resorption. Several lines of evidence suggest that
MIF is located upstream of these bone-resorbing molecules
and regulates their production. In vitro and in vitro studies
have shown that MIF has the properties of inducing and reg-
ulating the production of TNF, IL-1 IL-6, and NO [14,23–26].
An emerging body of data indicates that the role of MIF with-
in the cytokine cascade is to control the ‘set point’ and magni-
tude of the immune and inﬂammatory response [27].
Therefore, we may be allowed to suppose that the upregulation
of bone-resorbing molecules after OVX is, at least in part, trig-
gered by the rapid increase in serum MIF.
The molecular mechanism of the interaction between estro-
gen and the transcription of bone-resorbing cytokines has been
extensively studied. Translocation of nuclear factor-kappa B
(NF-jB) to the nucleus can upregulate the expression of pro-
inﬂammatory cytokines by binding of NF-jB to speciﬁc NF-
jB binding sites in the promoter regions of their genes [28].The inhibitory action of the activated estrogen receptor on
the binding of NF-jB to the IL-6 gene is one of the best-exam-
ined examples of cross-talk between estrogen receptors and
proinﬂammatory transcription factors [4]. Recent studies re-
vealed that estrogen also downregulated the production of
MIF in murine macrophages [15]. Sequence analysis of MIF
revealed that the 5 0-ﬂanking region of the MIF gene also con-
tains an NF-jB binding site, and the transcription of MIF was
inhibited by an inhibitor of NF-jB activation [29,30]. There-
fore, it is possible that MIF, like other proinﬂammatory cyto-
kines, could be induced by the activation of NF-jB, and
negatively regulated by estrogen via the repression of NF-jB
binding. Further investigations are under way to determine
the molecular mechanisms underlying the regulation of MIF
production by estrogen.
The exact role of MIF in the pathogenesis of postmeno-
pausal osteoporosis remains unelucidated; however, the results
of this study suggest that MIF could be a novel mediator be-
tween estrogen and osteoclasts, and could be a candidate as
a target for a novel osteoporosis therapy.
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